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Abstract
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K
(a, b, g , and d), with preclinical studies demonstrating broad
antitumor activity. We performed a first-in-human phase I study
in patients with advanced solid tumors.
Materials and Methods: Patients received oral GSK458 once or
twice daily in a dose-escalation design to define the maximum
tolerated dose (MTD). Expansion cohorts evaluated pharmacody-
namics, pharmacokinetics, and clinical activity in histologically
and molecularly defined cohorts.
Results: One hundred and seventy patients received doses
ranging from 0.1 to 3 mg once or twice daily. Dose-limiting
toxicities (grade 3 diarrhea, n ¼ 4; fatigue and rash, n ¼ 1)
occurred in 5 patients (n ¼ 3 at 3 mg/day). The MTD was
2.5 mg/day (MTD with twice daily dosing undefined). The
most common grade 3 treatment-related adverse events
included diarrhea (8%) and skin rash (5%). Pharmacokinetic
analyses demonstrated increased duration of drug exposure
above target level with twice daily dosing. Fasting insulin and
glucose levels increased with dose and exposure of GSK458.
Durable objective responses (ORs) were observed across
multiple tumor types (sarcoma, kidney, breast, endometrial,
oropharyngeal, and bladder cancer). Responses were not asso-
ciated with PIK3CA mutations (OR rate: 5% wild-type vs. 6%
mutant).
Conclusions: Although the MTD of GSK458 was 2.5 mg once
daily, twice-daily dosing may increase duration of target inhibi-
tion. Fasting insulin and glucose levels served as pharmacody-
namic markers of drug exposure. Select patients achieved durable
responses; however, PIK3CA mutations were neither necessary
nor predictive of response. Combination treatment strategies
and novel biomarkers may be needed to optimally target PI3K.
Clin Cancer Res; 22(8); 1932–9. 2015 AACR.
Introduction
The PI3K pathway is an important mediator of glucose metab-
olism, and in tumors, of cancer cell growth, survival, and metab-
olism (1–4). Upregulation of the pathway via activating muta-
tions (e.g., PIK3CA), loss of suppressor proteins (e.g., PTEN), or
activation of upstream receptor tyrosine kinases (e.g., Insulin-like
growth receptor and HER family) has been implicated in the
initiation and progression of numerous cancer subtypes, suggest-
ing its role as a therapeutic target across multiple solid tumor
malignancies and in preclinical models (5–9).
Several agents targeting the PI3K pathway (e.g., TORC1 inhi-
bitors) of various potency as well as narrow-target specificity have
been tested (10). GSK2126458 (GSK458) is a reversible, selective,
pan-PI3K ATP-competitive inhibitor with a Ki for the catalytic
p110a subunit in the subnanomolar range, with similar potency
against three somatic "hotspot" mutant forms of PI3K p110a
(E542K, E545K, and H1047R).
In vitro studies indicated antiproliferative effects of GSK458
across a broad panel of cancer cell lines. Breast cancer cell lines
harboring activating mutations in PIK3CA were among the most
sensitive to GSK458, whereas cell lines harboring RAS/RAFmuta-
tions were associated with poor response. Preclinical pharmaco-
dynamic analyses demonstrated a dose-dependent decrease in
phospho-AKT, a key downstream mediator of the PI3K signal
transduction pathway. In vivo, GSK458 displayed dose-dependent
delays in tumor growth across a range of xenograft models and
tumor regression in HCC1954 xenografts (PIK3CA-mutant and
KRAS wild-type breast cancer cell line). The biologic relevance of
wild-type or mutated PIK3CA and the correlation with on-target
side effects such as glycemic dysregulation has remained an
unanswered question.
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The primary objective of this first-in-human phase I dose-
escalation study was to determine the recommended phase II
dose (RP2D) of GSK458; secondary objectives included charac-
terization of pharmacokinetic and pharmacodynamic profiles
and to explore the relationship between pharmacokinetics, phar-
macodynamics, response prediction biomarkers, and clinical out-
comes. Pharmacodynamic biomarkers included 2[18F]fluoro-2-
deoxy-D-glucose (FDG)–PET, immunohistochemical assessment
of intratumoral protein phosphorylation of downstream effectors
of the PI3K pathway (AKT, ERK, and S6), and fasting serum
insulin and glucose levels.
Materials and Methods
Patient population
Patients were required to have advanced solid tumor malig-
nancies that had progressed on standard therapy, an Eastern
Cooperative Oncology Group (ECOG) performance status of 0
or 1, and adequate organ function including absolute neutrophil
count > 1.5  109/L, total bilirubin < 1.5  ULN, creatinine
< 2 mg/dL or creatinine clearance > 40 mL/min, fasting serum
glucose < 126mg/dL, and cardiac ejection fraction > LLN. Patients
with prior treatment with a PI3K inhibitor were excluded.
Study approval was obtained from the ethics committees at the
participating institutions and regulatory authorities. All patients
gave written informed consent. The study followed the Declara-
tion of Helsinki and good clinical practice guidelines.
Study design and treatment schedule
This was a phase I, multicenter, open-label, single-agent, dose-
escalation study of GSK458. The starting dose of GSK458 was
0.1 mg/day. The initial once-daily dosing schedule was based
upon in vivo xenograft data demonstrating improved efficacy with
once or twice-daily dosing compared with every 2-day dosing
schedule. Twice-daily dosing of GSK458 was subsequently tested
after initial pharmacokinetic/pharmacodynamic data suggested
that once-daily dosing did not achieve target serum concentra-
tions over a 24-hour interval.
The dose-escalation portion of the study used a 3þ3 escalation
schema, and also took into account predicted doses as determined
by Escalation with Overdose Control Bayesian Adaptive Design
Methodology (11). The MTD was defined as the exposure
expected to produce some degree of medically unacceptable
dose-limiting toxicitiy (DLT, q). For this study, the probability
of DLT (q) was set as q ¼ 0.25.
Additional patient cohorts consisted of the following: (i)
pharmacodynamic expansion cohorts, including (a) patientswho
underwent paired tumor biopsies and (b) patients who under-
went FDG-PET scans, (ii) predictive marker cohorts including
PIK3CA-mutated breast and urothelial carcinoma andKRASwild-
type endometrial carcinoma, (iii) safety profile expansion cohort
to better characterize safety profile and define RP2D, (iv) explor-
atory cohorts consisting of patients with renal cell, bladder, and
endometrial carcinoma enrolled without selection based upon
tumor genotyping. Dosing for the expansion cohorts occurred at
or below the MTD defined by the dose-escalation cohorts. Avail-
ability of archival tumor tissue was required for patients enrolled
into the predictive markers cohorts and optional for all others.
Sample size justification
The planned total sample sizewas between 175 to 225patients.
The sample size of the dose-escalation cohort was based upon the
3þ3 dose-escalation schema as outlined above. Up to 12 patients
per dose level were enrolled in the safety expansion cohorts to
better define the safety profile and RP2D of GSK458. The planned
sample size of each planned pharmacodynamic cohort was 15
evaluable patients to achieve 80% power with a ¼ 0.05 in
detecting an effect size of 0.7 in percent change from baseline in
prespecified pharmacodynamic markers.
For each predictive and exploratory cohort, it was assumed that
themaximumobjective response (OR) rate for an ineffective drug
was 0.1, and the minimum OR rate for an effective drug was 0.3.
Simon optimal two-stage design was used to test the null hypoth-
esis of 10% response proportion with 80% at a ¼ 0.05. If one or
fewer responses were observed in the first 10 patients enrolled per
cohort, and also upon reviewof the number of additional patients
with tumor regressions classified as stable disease, the cohort was
closed to accrual.
The actual final planned analyses were performed after 167
patients completed study treatment and the database was locked
on December 12, 2012.
Safety and efficacy assessments
Clinical and laboratory assessmentswere conducted at baseline
andweekly during cycle 1 (28-day cycle length) andonce per cycle
thereafter. Ambulatory blood glucose monitoring occurred daily
during cycle 1. Tumor responsebyRECIST1.0 criteriawas assessed
at baseline and every 2 cycles thereafter. Adverse events were
graded using Common Toxicity Criteria version 3.0.
Pharmacodynamic assessments
In selected pharmacodynamic cohorts, paired tumor biopsies
and FDG-PET scanswere performedwithin14days prior to starting
GSK458 and repeated during days 2 to 4 of cycle 1. Pre- and post-
dose biopsies were evaluated by IHC for protein expression of total
and phosphorylated forms of AKT, ERK, and P70s6K, phospho-
histone 3, phosphorylated proline-richAKT, andKi67proliferation
index. Serial fasting glucose and insulin samples were collected.
Pharmacokinetic assessments
Blood samples for GSK458 concentrations were obtained pre-
dose and up to 24 hours postdose on days 1 and 15 of cycle 1 for
patients treatedwith the daily dosing schedule. For the twice-daily
Translational Relevance
The results demonstrate a subset of patients with durable
responses to single-agent therapy, including two patients with
ongoing tumor responses lasting more than 4 years in dura-
tion. The data highlight the need to better define themolecular
profile of these "exceptional responders." Notably, a priori
selection of predictive biomarkers, including somatic PIK3CA
mutations, failed to enrich for clinical benefit or objective
response, highlighting the importance of developing novel
functional biomarkers to enrich for therapeutic benefit. The
modest single-agent activity observed calls into question the
development of PI3K inhibitors asmonotherapy for advanced
solid tumor malignancies and suggests that combination
therapy will be required.
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dosing schedule, samples were obtained up to 12 hours after each
dose (amandpm)ondays1 and15.GSK458blood concentration
was determined using validated LC/MS-MS. The lower limit of
quantification of GSK458 was 0.5 ng/mL. Standard pharmacoki-
netic parameters were computed by noncompartmental methods
(WinNonLin). Values assessed were area under the plasma-con-
centration time curve from time 0 to 24 or 12 hours (AUC0–24)
and (AUC0–12) for once- or twice-daily dosing, respectively, and
maximum blood concentration (Cmax) and time to Cmax (tmax).
Accumulation was determined by AUC day 15/AUC day 1.
Results
Study population
A total of 170 patients were enrolled between September 2009
and August 2012. Baseline characteristics of the enrolled patients
are shown in Table 1. Seventy percent of patients received three or
more prior lines of therapy in the advanced setting. Overall,
PIK3CA mutation status was known in 68 patients (40%), of
which 18 patients (26%) harbored somatic PIK3CAmutations at
the time of study enrollment.
Patient disposition is shown in Table 2. Sixty-five patients
(38%) enrolled onto the daily or twice-daily dose-escalation
phase, and 105 patients enrolled into one of the prespecified
expansion cohorts. The majority (79%) of patients discontinued
study therapy for disease progression. Two patients remained on
study treatment (>4 years' duration).
Determination of MTD
In the once-daily dose-escalation part of the study, 8 dose levels
were explored (Table 3). The first DLT (grade 3 diarrhea) occurred
at the 1.5 mg once-daily dose. This cohort was expanded without
further dose limiting events. Three DLTs (all grade 3 diarrhea
events) occurred at the 3 mg once-daily dose level, rendering this
the nontolerated dose (NTD). Patients were subsequently treated
at dose levels of 2mg and 2.5mg once daily without any observed
DLTs, establishing 2.5 mg as the MTD with once daily dosing
schedule.
Because of the observation of a shorter duration ofGSK458 drug
levels above target range with daily dosing, twice-daily dose esca-
lation was initiated at a dose of 0.75 mg twice daily, and 5 dose
levels were studied (Table 3). No DLTs were observed at the 2 mg
twice-daily dose level. One of the three patients experienced a DLT
(grade 3 fatigueþ grade 3 rash) at 2.5mg twice daily; however, due
to the decision to discontinue single-agent testing of GSK458,
further patients were not treated at this dose level; and therefore,
the MTD with twice-daily dosing could not be determined.
Safety results
The most common adverse events (any grade severity) experi-
enced on study were fatigue (45%), diarrhea (45%), nausea
(42%), decreased appetite (30%), and vomiting (26%; Table 4).
The most common grade  3 adverse events included diarrhea
(8%), hyperglycemia (>250 mg/dL; 6%), and skin rash (5%).
Nine patients (5%) experienced a treatment-related serious
adverse event, including four patients with diarrhea. Diarrhea
appeared to be an intermittent, self-limiting event for most
patients, with resolution reported in 82% of patients. Rash was
noted in 21 patients (12%), with most patients experiencing a
single occurrence (81%). The most common type of rash was
maculopapular in appearance; acneiform rash was rare
(2 patients). Hyperglycemia was noted in 37 patients (22%), was
mostly grade 1 or 2 in severity, and did not require dose adjust-
ment in the majority of patients (92%). Cardiac toxicity was
minimal with 2 (1%) patients experiencing post-baseline
decreases in ejection fraction below the lower limit of normal
and >10% from baseline. There were no significant effects on
mood noted. There were no treatment-related grade 5 adverse
events.
Table 1. Patient characteristics (N ¼ 170)
Gender, n (%)
Female 84 (49)
Male 86 (51)
Age in years, mean (range) 56.7 (22–85)
Race, n (%)
Caucasian 154 (91)
Asian 8 (5)
African American 6 (4)
Unknown 2 (1)
Ethnicity, n (%)
Hispanic (2)
Non-hispanic (98)
Body mass index, kg/m2 mean (range) 26.8 (18.2–48.5)
ECOG performance status, n (%)
0 57 (34)
1 113 (66)
Tumor histology, n (%)
Colon/rectum 31 (18)
Renal cell 24 (14)
Breast 22 (13)
Bladder 17 (10)
Endometrial 15 (9)
Melanoma 8 (5)
Ovary/primary peritoneal 6 (4)
Pancreas 4 (2)
Prostate 4 (2)
Other 39 (23)
Known PIK3CA mutation status at study entry, n (%)
Positive 18 (11)
Negative 50 (29)
Unknown 102 (60)
Number of lines of prior anticancer therapy, n (%)
1 20 (12)
2 29 (17)
3 35 (21)
4 24 (14)
5þ 60 (35)
Table 2. Patient disposition
Number of subjects enrolled per cohort, n (%)
Daily dosing–escalation cohort 43 (25)
Twice-daily dosing–escalation cohort 22 (13)
Safety expansion cohort 20 (12)
PD expansion cohort 36 (21)
Exploratory cohort (renal, endometrial, and bladder cancer) 40 (24)
Breast cancer with PIK3CA mutation 9 (5)
Reasons for study discontinuation, n (%)
Disease progression 136 (80)
Withdrawal of consent 12 (7)
Adverse event 9 (5)
Other 11 (7)
Therapy ongoing 2 (1)
Number of patients included in study populations, n (%)
Safety/toxicity 170 (100)
PK population 166 (98)
PD (blood) 170 (100)
PD (tumor) 25 (15)
Abbreviations: PD, pharmacodynamics; PK, pharmacokinetics.
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Pharmacokinetic analyses
Following single daily dosing, themedian tmax ranged from1 to
4 hours. Mean AUC0–24hrs and Cmax increased approximately in
proportion with doses from 0.1 to 0.4 mg daily and then from
0.75 mg to 3.0 mg/day but not across the whole dose range
(Supplementary Table S1 and Fig. 1A). As expected due to accu-
mulation of GSK458, the mean AUC0–12hrs and Cmax were gen-
erally higher following the second dose versus the first dose
with the twice-daily dosing schedule. The average time spent
> 20 ng/mL (the target dose level based on preclinical data) was
greater with twice-daily than once-daily dosing (21.2 hours
at 2 mg twice daily vs. 14.5 hours at the once-daily MTD of
2.5 mg; Fig. 1B). The terminal T1/2 and AUC0–>¥ could not be
determined due to the large %AUC extrapolation in >20% of
patients. Because of between-subject variability, pharmacokinetic
values overlapped across doses.
The repeat dose (day 15) pharmacokinetics of GSK458 dem-
onstrated that predose (Ctau) levels generally increased with dose,
but values were variable and overlapped across doses. Ctau values
were higher on twice-daily versus once-daily dosing schedule for
comparable cumulative daily doses (e.g., 2mgdaily vs. 1mg twice
daily). The mean accumulation ratio with daily and twice daily
dosing schedules was approximately 1.4.
Pharmacodynamic analyses
Putative biomarkers of the PI3K signaling pathway were pro-
spectively investigated. The approach included measurement of
phosphorylation levels of various downstream kinases in a pro-
spectively identified cohort of patients harboring tumors with
activating somatic PIK3CA mutations. Baseline and post-dose
tumor biopsies for immunohistochemichal analysis were
obtained in a total of 24 patients, with 13 patients having paired
evaluable biopsies. Eleven of the 13 patients were treated with
GSK458once daily. The percent change frombaseline in p-AKTH-
score was inconsistent and did not correlate with the PIK3CA
mutation status or with dose level of a patient (Fig. 2A).
For the subset of patients with both pharmacokinetic and
pharmacodynamic data available, the correlation between drug
exposure (AUC) and percent change from baseline in phosphor-
ylated-AKT H-score by IHC was weak and not significant
Table 3. Summary of DLTs by dose level
Dose (mg) Frequency Treated (n) Number of DLTs DLT
0.1 Once daily 7 0
0.2 Once daily 4 0
0.4 Once daily 5 0
0.75 Once daily 9 0
1.5 Once daily 14 1 Grade 3 diarrhea (n ¼ 1)
3.0 Once daily 9 3 Grade 3 diarrhea (n ¼ 3)
2.0 Once daily 38 0
2.5a Once daily 57 0
0.75 Twice daily 3 0
1.0 Twice daily 5 0
1.5 Twice daily 8 0
2.0 Twice daily 8 0
2.5 Twice daily 3 1 Grade 3 fatigue þ grade
3 rash (n ¼ 1)
a2.5 mg once daily established as MTD for single daily dosing. MTD for twice-daily dosing schedule not determined.
Table 4. Summary of adverse events (any grade severity) in 10% of patients across dose levels
Subjects, n (%)
Once-daily dosing Twice-daily dosing
0.1 0.2 0.4 0.75 1.5 2.0 2.5 3.0 0.75 1.0 1.5 mg 2.0 mg 2.5 mg Total
Event n ¼ 7 n ¼ 4 n ¼ 5 n ¼ 9 n ¼ 14 n ¼ 38 n ¼ 57 n ¼ 9 n ¼ 3 n ¼ 5 n ¼ 8 n ¼ 8 n ¼ 3 N ¼ 170
Any event 7 (100) 4 (100) 5 (100) 9 (100) 14 (100) 38 (100) 57 (100) 9 (100) 3 (100) 5 (100) 8 (100) 8 (100) 3 (100) 170
Diarrhea 0 0 0 6 (67) 3 (21) 15 (39) 32 (56) 6 (67) 0 2 (40) 6 (75) 4 (50) 3 (100) 77 (45)
Fatigue 2 (29) 1 (25) 1 (20) 2 (22) 9 (64) 14 (37) 32 (56) 5 (56) 1 (33) 2 (40) 3 (38) 2 (25) 3 (100) 77 (45)
Nausea 2 (29) 0 0 2 (22) 6 (43) 17 (45) 28 (49) 4 (44) 1 (33) 3 (60) 3 (38) 3 (38) 2 (67) 71 (42)
Decreased appetite 1 (14) 1 (25) 0 1 (11) 5 (36) 9 (24) 17 (30) 4 (44) 1 (33) 4 (80) 4 (50) 3 (38) 1 (33) 51 (30)
Vomiting 0 0 0 1 (11) 4 (29) 10 (26) 23 (40) 4 (44) 0 0 0 2 (25) 0 44 (26)
Hyperglycemia 0 1 (25) 1 (20) 0 2 (14) 5 (13) 12 (21) 4 (44) 0 1 (20) 2 (25) 2 (25) 1 (33) 31 (18)
Dyspnea 1 (14) 0 0 2 (22) 2 (14) 8 (21) 10 (18) 2 (22) 0 1 (20) 0 1 (13) 0 27 (16)
Pyrexia 1 (14) 0 1 (20) 1 (11) 5 (36) 1 (3) 12 (21) 2 (22) 0 1 (20) 1 (13) 0 0 25 (15)
Constipation 0 1 (25) 0 0 1 (7) 7 (18) 7 (12) 2 (22) 2 (67) 2 (40) 1 (13) 1 (13) 0 24 (14)
Mucositis 0 0 0 0 1 (7) 5 (13) 6 (11) 4 (44) 0 2 (40) 4 (50) 1 (13) 1 (33) 24 (14)
Back pain 0 1 (25) 0 2 (22) 0 7 (18) 8 (14) 0 1 (33) 3 (60) 0 1 (13) 0 23 (14)
Urinary tract infection 1 (14) 0 0 0 2 (14) 5 (13) 10 (18) 1 (11) 0 0 2 (25) 2 (25) 0 23 (14)
Abdominal pain 0 0 0 1 (11) 1 (7) 3 (8) 11 (19) 1 (11) 1 (33) 1 (20) 1 (13) 0 0 22 (13)
Rash 0 0 0 1 (11) 0 4 (11) 7 (12) 4 (44) 0 0 1 (13) 1 (13) 3 (100) 21 (12)
Cough 0 0 0 1 (11) 0 3 (8) 10 (18) 3 (33) 1 (33) 0 0 1 (13) 1 (33) 20 (12)
Peripheral edema 0 0 0 0 1 (7) 5 (13) 11 (19) 0 0 1 (20) 1 (13) 1 (13) 0 20 (12)
Anemia 0 1 (25) 0 1 (11) 2 (14) 4 (11) 5 (9) 3 (33) 2 (67) 0 0 1 (13) 0 19 (11)
Headache 2 (29) 0 1 (20) 3 (33) 1 (7) 3 (8) 3 (5) 2 (22) 0 1 (20) 2 (25) 1 (13) 0 19 (11)
Aspartate
aminotransferase
0 1 (25) 2 (40) 0 2 (14) 1 (3) 6 (11) 1 (11) 0 1 (20) 1 (13) 2 (25) 0 17 (10)
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(r ¼ 0.27; Fig. 2B). Similar patterns were observed for phos-
phorylated P70s6K and ERK (data not shown).
Paired FDG-PET scans were performed in 14 patients, all of
whom were treated with GSK458 once daily (Fig. 2C). Overall,
decrease in FDG avidity upon initiation of GSK458 treatment was
observed in 28 of 38 evaluable metastatic lesions (74%). There
was no consistent dose–effect relationship on FDG-PET scans by
metastatic lesion. The median change from baseline in sum of
SUVmax by patient varied from3.1 to 0.1 across the 0.75mg to 3
mg once-daily dosing levels.
In contrast, the percent change from baseline in fasting plasma
glucose levels on day 1 of study therapy was significantly asso-
ciated with GSK458 dose level (Fig. 2D). Likewise, the fold
increase in insulin from baseline to 6 hours postdose on cycle
1 day 1 was significantly associated with dose and serum con-
centration of GSK458 (data not shown).
Efficacy analyses
The maximum percent change from baseline in tumor mea-
surements is shown in Fig. 3. Forty-three patients (25%) had
nonmeasurable disease and/or discontinued study prior to first
restaging scans and thus were not evaluable for assessment of OR.
Overall, ORs were seen in 9 patients (5%; Supplementary Table
S2). Two of the nine ORs were observed in the twice-daily dosing
cohort (N¼ 27; 7% response rate). In the expansion cohort of 84
patients enrolled with breast, renal cell, bladder, or endometrial
cancer, there were a select group of patients with prolongedOR or
disease stabilization, including 5 (6%) patients treated with
GSK458 for greater than 6 months without disease progression
(Supplementary Fig. S1). Two patients with bladder and renal cell
carcinoma remain on therapy with ongoing partial and complete
responses, respectively, for more than four years duration.
Importantly, there did not appear to be enrichment for tumor
responses or prolonged disease stabilization in KRAS wild-type
endometrial cancer patients or in patients with tumors harboring
somatic PIK3CA mutations, with objective tumor response rates
of 7% and 6% respectively in these two prespecified expansion
cohorts.
Discussion
The dose-escalation/expansion study of the pan-class I PI3K
inhibitor GSK458 demonstrates that targeting the PI3K pathway
directly with this small-molecule inhibitor is well tolerated and
associated with single-agent activity in a small percentage of
patients across multiple tumor types in a heavily pretreated
patient population. Prolonged objective tumor responses and
disease stabilization was observed in several tumor types includ-
ing bladder and renal cell carcinoma. Overall, however, limited
single-agent activity was observed and a priori selection of molec-
ularly defined tumor subtypes including PIK3CA-mutant breast
and bladder cancer and KRAS wild-type endometrial cancer
did not enrich for tumor response or prolonged disease stabili-
zation. In accounting for these findings, several points warrant
consideration.
First, in contrast to prior reports (12–17), activating somatic
PIK3CAmutations did not appear to be a predictive biomarker of
clinical benefit in the expansion cohort, and the responses seen in
nonmutated patients suggest that in our population, PIK3CA
mutations were neither predictive nor necessary for response.
Baseline and early changes in FDG uptake on PET scan were
likewise neither associatedwith dose nor with subsequent clinical
response. The PI3K pathway is essential for many cellular func-
tions, and the on-target effects of GSK458 treatment on plasma
glucose and serum insulin levels suggest a strong inhibition of the
wild-type PI3K pathway. These results highlight the need formore
effective biomarkers to predict which subset of tumors are highly
dependent on PI3K/mTOR signaling for proliferation and there-
fore more likely to respond to targeted PI3K inhibition. Without
such biomarkers, the clinical development of targeted PI3K/
mTOR pathway inhibitors will be hindered.
Emerging evidence indicates that PI3K inhibitors may have
limited single-agent activity in tumors with PIK3CA mutations
due to compensatory activation of alternative signaling pathways
including mitogen-activated protein (MAP) kinase, particularly
in tumors harboring coexisting RAS mutations (18). Other a
isoform-specific and pan-class inhibitors of PI3K, including
BYL719 and BKM120, respectively, have also demonstrated lim-
ited single-agent activity across a variety of solid tumor malig-
nancies including those harboring PIK3CAmutations (19, 20). In
contrast to activating mutations in other oncogenes (e.g., EGFR
and BRAF) in which significant single-agent activity is observed,
combination treatment strategies may be necessary to effectively
target the PI3Kpathway. In a prior retrospective reviewofPIK3CA-
mutant tumors treated with single-agent PI3K inhibitors versus
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A, mean blood concentration versus time on day 1 with single daily dosing. B,
mean blood concentration versus time on day 1 with twice-daily dosing.
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combination therapy (including cotargeting of MAP kinase
pathway), progression-free survival was significantly longer with
combination therapy (18). A prospective clinical trial combining
GSK458 with the MEK inhibitor trametinib recently demonstrat-
ed prolongeddisease stabilization in a subset of tumors harboring
KRAS mutations (21).
The study results also highlight the importance of pharmaco-
kinetic/pharmacodynamic data to define the optimal biologic
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dose in a first-in-patient study of a targeted anticancer therapy.
Pharmacokinetic/pharmacodynamic modeling using mouse
BT474 xenografts yielded a sustained mean target serum concen-
tration of >20 ng/mL as the expected IC67 for AKT phosphoryla-
tion with range of 6.6 to 60 ng/mL to account for potential
translation differences between mice and humans. Pharmacoki-
netic data from the daily dosing schedule suggested that the
target serum concentration of >20 ng/mLwas not being sustained
over a 24-hour interval. In addition, significant interpatient var-
iability in drug exposure was observed across the once-daily
dosing levels. These two factors likely contributed to the lack of
dose- and exposure-dependent effect observed in the pharmaco-
dynamic analyses with daily dosing of GSK458 and may have
impacted the observed antitumor activity. The twice-daily dosing
schedule achieved more consistent serum levels above the target
exposure. Whether twice-daily dosing of GSK458 translates into
more effective target inhibition and enhanced antitumor activity
requires further clinical evaluation as pharmacodynamic analyses
were nearly entirely limited to the once-daily dosing cohort and
the MTD was not reached with twice-daily dosing.
GSK458 was fairly well tolerated. The frequency of adverse
events appeared to be similar with once-daily versus twice-daily
dosing. Diarrhea was a common clinical event; however, it was
largely grade 1–2 in severity for most patients, with grade 3
diarrhea (>7 stools above baseline/day) observed in 8% of
enrolled patients. Diarrhea appeared to be self-limiting and
responsive to temporary dose interruptions and resolved in
more than 80% of patients at the time of last study reporting.
Hyperglycemia, a class effect (and potential pharmacodynamic
biomarker) of PI3K pathway inhibition, was observed in 18%
of patients on study and was mostly grade 1–2 in severity.
Hyperglycemia was commonly managed with oral agents (e.g.,
metformin); the initiation of insulin during protocol therapy
was a rare event. Other class effects of PI3K pathway inhibition
were observed, including rash and mucositis, both managed
effectively with temporary dose holds and/or initiation of
topical steroid treatment. Interestingly, in contrast to other
PI3K inhibitors such as BKM120, effects on mood were uncom-
mon, suggesting potentially a differential penetration across
the blood–brain barrier or other off-target differences in recep-
tor inhibition (20).
Conclusion
The MTD with daily dosing of GSK458 is 2.5 mg/day.
However twice-daily dosing may optimize target inhibition
across a 24-hour interval. Pharmacodynamic analyses showed
a dose-dependent increase in fasting insulin and glucose levels
that may serve as a pharmacologic biomarker of drug exposure.
Antitumor activity of GSK458 was not enriched in KRAS wild-
type endometrial cancer or in PIK3CA-mutant cancers in this
study, highlighting the need for more effective predictive bio-
markers of the PI3K signaling pathway. GSK458 is being
evaluated in combination with other targeted agents as well
as in noncancerous indications in which PI3K upregulation is
implicated in disease etiology (e.g., idiopathic pulmonary
fibrosis; NCT01725139).
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